Tom Wickham

Company: GentiBio

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: Uniting Industry & Academia to Accelerate Cell Therapy Development for Autoimmune Disease

Moderator – Greg Deener, Chief Executive Officer, iCell Gene Therapeutics 11:30 am

• How can we foster increased partnerships between industry and academic/clinical institutions to strengthen our understanding of current autoimmune indications? • How do we build on the established experiences where academic clinical trials provided early POC for cell therapy in AID to attract investment and clinical development and commercialization of cell therapies in the autoimmune…Read more

day: Day One Track B, AM

Engineered Tregs to Designed to Overcome Therapeutic Bottlenecks for Achieving Therapeutic Benefit in Type 1 Diabetes 1:00 pm

• Discussing the advantages of GNT-122, including a targeted, stable phenotype with a chemically inducible signaling complex (CISC) to overcome the IL-2 scarce environment in T1D • Highlighting the importance of Tregs in regulating acute inflammatory responsesRead more

day: Day One Track A, PM